Single Dose Escalation Study of Bivatuzumab Mertansine in Patients With Advanced Squamous Cell Carcinoma of the Head and Neck

Phase 1

Completed

• Conditions: Head and Neck Neoplasms
• Interventions: Drug: bivatuzumab mertansine

• Registration Number: NCT02254018
• Lead Sponsor: Boehringer Ingelheim

Brief Summary

maximum tolerated dose (MTD), safety, pharmacokinetics, efficacy of bivatuzumab mertansine

Detailed Description

Not available

Study Timeline

• Study Start: 2002-09-01
• Primary Completion: 2005-02-01
• Study First Submitted: 2014-09-30
• Study First Submitted QC: 2014-09-30
• Study First Posted: 2014-10-01
• Status Verified: 2023-10
• Last Update Submitted: 2023-10-23
• Last Update Posted: 2023-10-24

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 31

Inclusion Criteria

1. male and female patients aged 18 years or older
2. patients with histologically confirmed squamous cell carcinoma of the head and neck
3. patients with local and / or regional recurrent disease or distant metastases who are refractory to or not amenable to established treatments
4. measurable tumour deposits by one or more radiological techniques (MRI, CT)
5. life expectancy of at least 6 months
6. Eastern Cooperative Oncology Group (ECOG) performance score ≤ 2
7. patients must have given written informed consent (which must be consistent with International Conference of Harmonisation-Good Clinical Practice (ICH-GCP) and local legislation)

Read More

Exclusion Criteria

1. hypersensitivity to humanised or murine antibodies, immunoconjugates or the excipients of the trial drugs
2. known secondary malignancy requiring therapy
3. active infectious disease
4. brain metastases
5. neuropathy grade 2 or above (excluding pre-existing neuropathy of cranial nerves due to surgery, radiotherapy or tumour growth)
6. absolute neutrophil count less than 1,500/mm3
7. platelet count less than 100,000/mm3
8. bilirubin greater than 1.5 mg/dl (> 26 μmol/L, système internationale (SI) unit equivalent)
9. aspartate amino transferase (AST) and/or alanine amino transferase (ALT) greater than 3 times the upper limit of normal
10. serum creatinine greater than 1.5 mg/dl (> 132 μmol/L, SI unit equivalent)
11. concomitant non-oncological diseases which are considered relevant for the evaluation of the safety of the trial drug
12. chemo- or immunotherapy within the past three weeks prior to treatment with the trial drug or during the trial
13. radiotherapy to head and neck region within the past four weeks before inclusion or during the trial
14. men and women who are sexually active and unwilling to use a medically acceptable method of contraception
15. pregnancy or lactation
16. treatment with other investigational drugs or participation in another clinical trial within the past three weeks before start of therapy or concomitantly with this trial
17. patients unable to comply with the protocol

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
bivatuzumab mertansine	bivatuzumab mertansine	single dose escalation

Primary Outcome Measures

Name	Time	Method
Maximum tolerated dose (MTD) of bivatuzumab mertansine	up to day 21

Secondary Outcome Measures

Name	Time	Method
Concentration of CD44v6 recognising IgG antibodies (anti-CD44v6-IgG)	up to day 21
Number of patients with adverse events	up to day 21	grading according to the common toxicity criteria (CTC)
Number of patients with clinically significant changes in laboratory parameters	up to day 21
Number of patients with clinically significant changes in vital signs	up to day 21
Concentration of bivatuzumab mertansine	up to day 21
Tumor response	up to 1 year	according to the response evaluation criteria in solid tumours (RECIST)
Number of patients with development of human anti-human antibodies (HAHA)	up to day 21